Saturday, February 21, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Innovations & Investing

Journalists Must Address Lax Oversight on Research Data

Report what doesn't add up

Denise-Marie Ordway by Denise-Marie Ordway
May 15, 2024
in Innovations & Investing
0
Journalists Must Address Lax Oversight on Research Data

The Climate Reality Project

Uri Simonsohn is an outspoken advocate for open science — adding transparency to the research process and helping researchers share what they’ve learned in greater detail with a broad audience.

Many people know Simonsohn for his data analyses on Data Colada, a blog about social science research he writes with two other behavioral scientists, Leif Nelson and Joseph Simmons. The three scholars, who co-direct the Wharton Credibility Lab at the University of Pennsylvania, occasionally use the blog to spotlight evidence of suspected fraud they’ve found in academic papers.

In his role at the Credibility Lab and as a professor at Esade Business School in Barcelona, Simonsohn travels to speak on issues around scientific integrity and data science. During his recent visit to Harvard University, The Journalist’s Resource asked for his thoughts on how journalists can improve their coverage of academic fraud and misconduct.

Here are three big takeaways from our conversation.

1. Before covering academic studies, ask researchers about preregistration.

Preregistration is “the practice of documenting your research plan at the beginning of your study and storing that plan in a read-only public repository such as OSF Registries or the National Library of Medicine’s Clinical Trials Registry,” according to the nonprofit Center for Open Science. Simonsohn says preregistration helps prevent research fraud. When researchers create a permanent record outlining how they intend to conduct a study before they start, they are discouraged from changing parts of their study — for instance, their hypothesis or study sample — to get a certain result.

Simonsohn adds that preregistration also reduces what’s known as “p-hacking,” or manipulating an analysis of data to make it seem as though patterns in the data are statistically significant when they are not. Examples of p-hacking: Adding more data or control variables to change the result or deciding after the analysis is complete to exclude some data. (For more on statistical significance, read our tip sheet on the topic.)

Preregistration is particularly important when researchers will be collecting their own data, Simonsohn points out. It’s easier to alter or fabricate data when you collect it yourself, especially if there’s no expectation to share the raw data.

While preregistration is the norm in clinical trials, it’s less common in other research fields. About half of psychology research is preregistered as is about a quarter of marketing research, Simonsohn says. A substantial proportion of economic research is not, however, because it often relies on data collected by other researchers or nonprofit organizations and government agencies such as the U.S. Census Bureau.

Simonsohn urges journalists to ask researchers whether they preregistered their studies before reporting on them. He likened reporting on research that isn’t preregistered to driving a car that hasn’t been inspected. The car might be perfectly safe, but you can’t be sure because no one has had a chance to look under the hood.

“If the person says ‘no,’ [the journalist] could ask, ‘Oh, how come?’” he says. “And if they don’t provide a compelling reason, the journalist could say ‘You know, I’m not going to cover work that hasn’t been preregistered, without a good rationale.’”

Research registries themselves can be a helpful resource for journalists. The Center for Open Science lets the public search for and read the thousands of preregistered research plans on its Open Science Framework platform. Researchers who preregister their work at AsPredicted, a platform Simonsohn helped create for the Wharton Credibility Lab, can choose whether and when to make their preregistered research plan public.

2. Report on the lack of oversight of research data collection.

Journalists and the public probably don’t realize how little oversight there is when it comes to collecting and analyzing data for research, Simonsohn says. That includes research funded by the federal government, which gives colleges, universities and other organizations billions of dollars a year to study public health, climate change, new technology and other topics.

Simonsohn says there’s no system in place to ensure the integrity of research data or its analysis. Although federal law requires research involving human subjects to be reviewed by an Institutional Review Board, the primary goal of these independent committees is protecting the welfare and rights of study participants.

Academic papers are reviewed by a small group of experts before a scholarly journal will publish them. But the peer-review process isn’t designed to catch research fraud. Reviewers typically do not check the authors’ work to see if they followed the procedures they say they followed to reach their conclusions.

Simonsohn says journalists should investigate the issue and report on it.

“The lack of protection against fraud is a story that deserves to be written,” he says. “When I teach students, they’re shocked. They’re shocked that when you submit a paper to a journal, [the journal is] basically trusting you without any safeguards. You’re not even asked to assert in the affirmative that you haven’t done anything wrong.”

Journalists should also examine ways to prevent fraud, he adds. He thinks researchers should be required to submit “data receipts” to organizations that provide grant funding to show who has had access to, changed or analyzed a study’s raw data and when. This record keeping would be similar to the chain of custody process that law enforcement agencies follow to maintain the legal integrity of the physical evidence they collect.

“That is, by far, the easiest way to stop most of it,” Simonsohn says.

3. Learn about open science practices and the scientists who expose problematic research.

Nearly 200 countries have agreed to follow the common standards for open science that UNESCO, the United Nations’ scientific, educational and cultural organization, created in 2021. In December, UNESCO released a status report of initiatives launched in different parts of the globe to help researchers work together in the open and share what they’ve learned in detail with other researchers and the public. The report notes, for example, that a rising number of countries and research organizations have developed open data policies.

As of January 2024, more than 1,100 open science policies were adopted by research organizations and research funders worldwide, according to the Registry of Open Access Repositories Mandatory Archiving Policies, which tracks policies requiring researchers to make their “research output” public.

In the U.S., the universities and university departments that have adopted these policies include Johns Hopkins University, University of Central Florida, Stanford University’s School of Education and Columbia University’s School of Social Work. Such policies also have been adopted at Harvard Kennedy School and one of its research centers, the Shorenstein Center on Media, Politics and Public Policy, which is where The Journalist’s Resource is housed.

Simonsohn recommends journalists learn about open science practices and familiarize themselves with research watchdogs such as Nick Brown, known for helping expose problems in published studies by prominent nutrition scientist Brian Wansink.

Retraction Watch, a website that tracks research retractions, maintains a list of more than two dozen scientific sleuths. Elisabeth Bik, a microbiologist and science integrity consultant who has been called “the public face of image sleuthing,” was a guest speaker in The Journalist’s Resource’s recent webinar on covering research fraud and errors.

Here are some of the open science organizations that journalists covering these issues will want to know about:

  • The Virginia-based Center for Open Science.
  • The Berkeley Initiative for Transparency in the Social Sciences.
  • Yale University Open Data Access (YODA) Project, an online platform for sharing clinical trial research data.
  • VEDA (Visualization, Exploration, and Data Analysis), NASA’s open-source platform that allows researchers to collaborate on Earth science studies.
  • MedRxiv (pronounced “med-archive”) is an online platform owned and operated by Cold Spring Harbor Laboratory. Researchers can use it to share preprint research — academic papers that present preliminary findings and have not been peer reviewed — on medical, clinical and health science topics.

This article first appeared on The Journalist’s Resource and is republished here under a Creative Commons license.

Source: The Journalist’s Resource
ShareTweet
Denise-Marie Ordway

Denise-Marie Ordway

Denise-Marie Ordway has received a multitude of national, regional and state-level journalism awards and was named as a Pulitzer Prize finalist in 2013 for an investigative series she led that focused on hazing and other problems at Florida A&M University.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions.

Takeaways
GLP-1 medications are not linked to pancreatic cancer.
Peer-reviewed studies debunk misinformation about GLP-1s.
Anecdotal evidence is not reliable for general conclusions.
Observational studies have limitations in generalizability.
Understanding study design is crucial for evaluating claims.
Symptoms should be discussed in the context of clinical conditions.
Not all side effects reported are relevant to every patient.
Observational studies can provide valuable insights but are context-specific.
Patients should critically assess the relevance of studies to their own experiences.
Engagement in discussions about specific studies can enhance understanding

Chapters
00:00
Debunking GLP-1 Medication Myths
02:56
Understanding Clinical Study Designs
05:54
The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • The Prevention Gap in Dementia Care

    The Prevention Gap in Dementia Care

    0 shares
    Share 0 Tweet 0
  • Healthcare in Space

    1 shares
    Share 0 Tweet 0
  • Healthcare Natural Rights

    0 shares
    Share 0 Tweet 0
  • Heat Safety Tips Every Pregnant Mother Should Know

    0 shares
    Share 0 Tweet 0
  • What is the 411 on the New 988 Hotline?

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy